A Phase I Clinical Trial on Combined (Neo-)Adjuvant Intravenous Plus Intracranial Administration of Ipilimumab and Nivolumab in Recurrent Glioblastoma

Trial ID: NCT06097975

Interventional - Phase 1 - Active, not recruiting

The goal of this phase I interventional study is to determine the safety and feasibility of the proposed investigational (neo-)adjuvant treatment regimen in patients with resectable reccurent glioblastoma. Participants will: * receive neo-adjuvant administration of intravenous immunotherapy * followed by a maximal safe neurosurgical resection * afterwards, immunotherapy will be injected into the brain tissue * followed by insertion of an Ommaya reservoir * postoperatively, administration of immunotherapy will be continued

Conditions

• Recurrent Glioblastoma

Interventions

• Neo-adjuvant nivolumab and ipililumab IV + adjuvant nivolumab and ipililumab IV
• Neurosurgery and intracavitary injection nivolumab and ipililumab
• Adjuvant nivolumab IV + nivolumab and ipililumab intracavitary

Sponsor

Universitair Ziekenhuis Brussel

Source: ClinicalTrials.gov

Search more clinical trials on myTomorrows